More ROR1s enter the clinic
The conjugates SYS6005 and TQB2101 feature among first-in-human study entrants.
Like Crest, Potomac succeeds up to a point
Imfinzi hits on disease-free survival, but BCG won't be displaced.
Revolution gets selective
The group’s latest update focused on new data with the KRAS G12C inhibitor elironrasib.
Ivonescimab takes on pancreatic cancer
Meanwhile, Exelixis and AstraZeneca continue to invest in pivotal trials of blockbuster follow-ons.
Takeda says no to B7-H3
TAK-280 is among the group's discarded projects, although it’s a T-cell engager, not an ADC.
Lantheus calls time on me-too Pluvicto
Final survival analysis draws a blank, and Lantheus throws in the towel.
